We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Binding Site Announces Hevylite®  Assay Patent Approval
News

Binding Site Announces Hevylite® Assay Patent Approval

Binding Site Announces Hevylite®  Assay Patent Approval
News

Binding Site Announces Hevylite® Assay Patent Approval

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Binding Site Announces Hevylite® Assay Patent Approval"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Measurement of immunoglobulin heavy/light chains allows, for the first time, accurate calculation of immunoglobulin heavy/light chain ratios, e.g. IgGκ/IgGλ, an inventive step recognised by Patent Offices in the USA, Europe and Japan. 

In continuation of Binding Site’s innovative approach to protein detection in B cell disorders, patents covering the specific Hevylite® antibodies which recognise conformational epitopes, methods to concurrently measure heavy/light chain and free light chains together in multiplex assays, and production of heavy/light chain ratios using ELISA, Flow Cytometry or bead based assays have also been granted.

Hevylite® assays to measure the concentration of each immunoglobulin subtype i.e. IgGκ, IgGλ, IgAκ, IgAλ, IgMκ, IgMλ are CE marked and FDA cleared. The assays are currently in routine use in a number of countries, are being evaluated by many institutions worldwide and have been the subject of more than 20 papers and around 200 poster publications. These new assays overcome many of the issues seen when using traditional electrophoresis methods such as lower sensitivity and co-migration of bands, plus it gives information about the uninvolved heavy/light chain pair, e.g. IgAλ in an IgAκ myeloma patient.

Hevylite® is now incorporated into prestigious guidelines published by the British Committee for Standards in Haematology. This inclusion reflects the increasing number of publications showing the benefits of Hevylite® in a laboratory and clinical setting.  Download your free copy of the BCSH Guidelines here  

Advertisement